Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

Journal Article · · ACS Medicinal Chemistry Letters
 [1];  [1];  [2];  [2];  [2];  [1];  [1];  [2];  [2];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1] more »;  [1];  [1];  [1];  [1];  [1];  [1] « less
  1. Merck Research Lab., Kenilworth, NJ (United States)
  2. Merck Research Lab., Boston, MA (United States)
+ Show Author Affiliations

A new subseries of substituted piperidines as p53-HDM2 inhibitors exemplified by 21 has been developed from the initial lead 1. Research focused on optimization of a crucial HDM2 Trp23–ligand interaction led to the identification of 2-(trifluoromethyl)thiophene as the preferred moiety. Further investigation of the Leu26 pocket resulted in potent, novel substituted piperidine inhibitors of the HDM2-p53 interaction that demonstrated tumor regression in several human cancer xenograft models in mice. The structure of HDM2 in complex with inhibitors 3, 10, and 21 is described.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
USDOE
OSTI ID:
1404955
Journal Information:
ACS Medicinal Chemistry Letters, Journal Name: ACS Medicinal Chemistry Letters Journal Issue: 3 Vol. 7; ISSN 1948-5875
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (26)

Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn journal July 1997
p53 and Human Cancer: The First Ten Thousand Mutations book January 1999
Substituted piperidines as HDM2 inhibitors journal February 2014
Core modification of substituted piperidines as Novel inhibitors of HDM2–p53 protein–protein interaction journal April 2014
The p53 orchestra: Mdm2 and Mdmx set the tone journal May 2010
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design journal April 2011
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors journal May 2013
A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice journal June 2013
Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction journal March 2014
Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment: Miniperspective journal November 2014
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development journal January 2014
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor journal February 2014
Awakening guardian angels: drugging the p53 pathway journal December 2009
MDM2, MDMX and p53 in oncogenesis and cancer therapy journal January 2013
p53 in health and disease journal April 2007
Unleashing the power of p53: lessons from mice and men journal January 2006
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 journal February 2004
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene journal August 1990
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain journal November 1996
The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise journal January 2011
Mapping of the p53 and mdm-2 interaction domains. journal July 1993
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present) journal January 2013
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer journal November 2008
Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design journal January 2005
Small Molecule Inhibitors of the p53-MDM2 journal July 2008
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting journal February 2005

Cited By (4)

Identification of Kinases Responsible for p53-Dependent Autophagy journal May 2019
Chalcogen Bonding in Protein−Ligand Complexes: PDB Survey and Quantum Mechanical Calculations journal July 2018
Inhibiting mechanism of small molecule toward the p53-MDM2 interaction: A molecular dynamic exploration journal July 2018
BindingDB Entry 50047479: Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors. dataset January 2017

Figures / Tables (14)

Figure 2(p. 2)figure Figure 2
Figure 1(p. 2)figure Figure 1
Figure 3(p. 2)figure Figure 3
Scheme 1(p. 2)figure Scheme 1
Scheme 2(p. 2)figure Scheme 2
Figure 4(p. 3)figure Figure 4
Table 1(p. 3)table Table 1
Table 2(p. 3)table Table 2
Figure 5(p. 4)figure Figure 5
Figure 6(p. 4)figure Figure 6
Table 3(p. 4)table Table 3
Table 4(p. 4)table Table 4
Figure 7(p. 5)figure Figure 7
Figure 8(p. 5)figure Figure 8

Similar Records

Hdm2 and Nitric Oxide Radicals Contribute to the P53-Dependent Radioadaptive Response
Journal Article · Sun Jun 01 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21124289
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists that Activate
Journal Article · Fri Dec 31 23:00:00 EST 2004 · J. Med. Chem. · OSTI ID:913774
Potent pyrrolidine- and piperidine-based BACE-1 inhibitors
Journal Article · Mon Aug 18 00:00:00 EDT 2008 · Bioorg. Med. Chem. Lett. · OSTI ID:1006759

Related Subjects

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
60 APPLIED LIFE SCIENCES
HDM2
cancer
p53
protein−protein interaction